Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Strs Ohio

Strs Ohio lowered its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 13.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,200 shares of the company’s stock after selling 3,700 shares during the quarter. Strs Ohio’s holdings in Twist Bioscience were worth $892,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Federated Hermes Inc. acquired a new position in Twist Bioscience during the third quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. raised its position in shares of Twist Bioscience by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock worth $30,000 after buying an additional 721 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares during the period. International Assets Investment Management LLC boosted its holdings in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after acquiring an additional 3,907 shares during the last quarter. Finally, Caprock Group LLC purchased a new stake in Twist Bioscience during the fourth quarter valued at about $282,000.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Robert Chess sold 4,110 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total value of $143,767.80. Following the sale, the director now directly owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,037 shares of company stock valued at $384,092. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $30.75 on Thursday. Twist Bioscience Co. has a one year low of $11.46 and a one year high of $43.21. The stock’s 50 day moving average price is $35.15 and its 200 day moving average price is $30.32.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business had revenue of $71.50 million during the quarter, compared to the consensus estimate of $67.59 million. During the same period in the prior year, the firm earned ($0.74) earnings per share. The business’s quarterly revenue was up 31.8% compared to the same quarter last year. As a group, research analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. The Goldman Sachs Group upgraded Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Barclays reduced their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Finally, Scotiabank raised their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a research note on Monday, February 5th.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.